Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and immunogenicity of meningococcal and pneumococcal vaccination in adults living with HIV
2020-000863-22Phase 4Active
- Sponsor
- Thomas Benfield
- Start
- May 2020
- Modality
- Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4 trial of Meningococcal polysaccharide vaccine group W-135, meningococcal group B vaccine, pneumococcal 13-valent conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine in human immunodeficiency virus infection (HIV), meningococcal disease and pneumococcal disease (2 arms), sponsored by Thomas Benfield. Primary endpoint: Primary immunogenic response. Started May 2020; status: active.
02
Drugs
Meningococcal polysaccharide vaccine group W-135meningococcal group B vaccinepneumococcal 13-valent conjugate vaccine23-valent pneumococcal polysaccharide vaccine
03
Conditions
human immunodeficiency virus infection (HIV)meningococcal diseasepneumococcal disease
Beyond the preview
Go deeper on 2020-000863-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000863-22.